quotingBiogen Presents Positive Results From Phase 2 IGNAZ Study Of Felzartamab In Iga Nephropathy At American Society Of Nephrology (ASN) Kidney Week 2024
note126t…4asv
https://menafn.com/1108821056/Biogen-Presents-Positive-Results-From-Phase-2-IGNAZ-Study-Of-Felzartamab-In-Iga-Nephropathy-At-American-Society-Of-Nephrology-ASN-Kidney-Week-2024
ScienceNode on Nostr: Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis ...
Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis worldwide. Felzartamab is an investigational therapeutic human monoclonal antibody directed against CD38.